Durata Therapeutics (NASDAQ:DRTX) is a biotech company focused on the development of novel antibiotics for acute infectious skin diseases. While Durata currently does not produce any revenues, their lead product Dalbavancin will produce significant revenue streams after FDA approval and commercialization.
Dalbavancin is an intravenous antibacterial treatment for acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible Gram-positive bacteria. This once a week two-dose treatment requires only a 30 min peripheral IV consisting of first 1000mgs followed up 8 days later by an additional 500mgs. If approved, Dalbavancin would be the first drug of its type for the treatment ABSSSI.
To put that into comparison, an example of the current process for treating complicated skin...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|